Akebia (AKBA) Therapeutics announced that it has commenced an underwritten public offering. All shares are being offered by Akebia. Leerink Partners and Piper Sandler & Co. are acting as joint bookrunning managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKBA:
- Akebia Therapeutics’ Strong Market Performance and Strategic Initiatives Drive Buy Rating
- Akebia price target raised to $6 from $4 at Piper Sandler
- Akebia Therapeutics Faces Global Regulatory Challenges Amid Brexit and EU Changes
- Akebia Therapeutics Reports Progress in Vafseo Launch
- Akebia Therapeutics’ Earnings Call Highlights Vafseo Success